Celebration 67 years The Stephan Angeloff Institute of Microbiology


Microbiologia Balkanica 2013 - 8th Balkan Congress of Microbiology, Veliko Tarnovo, Bulgaria


Pitagor 2012 awarded to Assoc. Prof. Andrey Tchorbanov from The Stephan Angeloff Institute of Microbiology


Meeting of the President of BAS prof. Nikola Sabotinov with Dr. Mark Jouan from RIIP


Official ceremony of Academic degrees diploma awards


Pitagor 2011 awarded to two researchers from The Stephan Angeloff Institute of Microbiology



Закон за развитие на академичния състав в Република България



Правилник за прилагане на Закона за развитието на академичния състав в Република България



Процедури по закона за развитие на академичния състав в Република България



science daily















































Bulgarian Academy of Sciences


Ministry of Education and Science


National Science Fund


Central Library of BAS


Union of Scientists in Bulgaria


Comission: Horizon 2020

Institut Pasteur






PubMed Cenral




















Head: Associate Professor Andrey Tchorbanov, PhD


Tel: +359 2 979 63 57


e-mail: tchorban@microbio.bas.bg





LABORATORY of Infectious Immunology and Inflammation


Head: Professor Nina Ivanovska, DSc


e-mail: nina@microbio.bas.bg



Laboratory of Experimental Immunology


Head: Associate Professor Andrey Tchorbanov, PhD


e-mail: tchorban@microbio.bas.bg


LABORATORY of Experimental Immunotherapy

Head: Associate Professor Anastas Pashov, PhD

е-mail: a_pashov@microbio.bas.bg



Most Important results



  • Pathological DNA-specific B and T cells in SLE are logical targets for a selected therapeutic intervention. We have constructed chimeric molecules by coupling of different epitope-specific peptides to monoclonal antibodies. Our data show that it is possible to suppress selectively the activity of targeted autoreactive B and T-lymphocytes and to change the natural course of an autoimmune disease in mouse models or humanized transfer models of lupus by administering chimeric molecules that cross-link the inhibitory receptors with the immunoglobulin B cell receptor.

  • Introduction of DNA vaccines is a new approach to vaccination. Such a hybrid DNA molecules were constructed by us, encoding a T and B cell epitope-containing influenza hemagglutinin peptide and a scFv antibody fragment binding to mouse complement receptors I and II or human FcγRI. A single or double immunization with a plasmid containing the described construct induced a strong anti-influenza cytotoxic response lasting for more than six months and a weak antibody response.

  • We have worked on new therapeutic strategies in sepsis as there is an urgent unmet medical need for new treatments for this disease. Our therapeutic approach consists of the development and use of improved immunoglobulins “next generation” immunoglobulin preparations with enhanced
    anti-inflammatory activity.

  • We have characterised the role of properdin, a positive regulator of the complement system, in experimental models of sepsis and arthritis. Our studies demonstrate that properdin deficiency attenuates the symptoms of Zy-induced shock and exacerbates LPS-induced shock. It uncovers, for the first time, a relationship between properdin and macrophage as well as platelet functions in models of nonspetic shock. Our data showed that properdin, appeared to have a protective role in the processes of joint erosion which suggest that alternative pathway of complement might be actively involved in the chronic inflammation in rheumatoid arthritis. Another strand of our work characterises the antiinflammatory action of tyrosine kinase inhibitors in models of sepsis, particularly via STAT signaling

  • We have contributed to osteoimmunology research by determining on a molecular level the manner in which inflammation impairs bone formation and the extent to which signalling pathways are altered as a consequence. The investigations are carried out in patients with osteoarthritis and in a murine model of collagenase-induced osteoarthritis. Current work is focused on application of glucosamine as a potential antiarthritic agent. The mechanism of its action is studied with regard to neutrophils, key cytokines and chemokines and also RANKL signaling in relation to events leading to osteoclastogenesis.